Anna Berglind

Trial of Anifrolumab in Active Systemic Lupus Erythematosus

Eric F. Morand, Richard Furie, Yoshiya Tanaka et al. · New England Journal of Medicine · 2019 · 1.2K citations · Full text

Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial

Richard Furie, Eric F. Morand, Ian N Bruce et al. · The Lancet Rheumatology · 2019 · 442 citations · Full text

Inflammation, Autoimmune Disease, Systemic Lupus Erythematosus Treatment +10

Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials

Eric A. F. Simões, Shabir A. Madhi, William J. Muller et al. · The Lancet Child & Adolescent Health · 2023 · 283 citations · Full text

Asthma, Respiratory Syncytial Virus, Respiratory Diseases +9

Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab

Eric F. Morand, Teodora Trasieva, Anna Berglind et al. · Annals of the Rheumatic Diseases · 2018 · 94 citations · Full text

Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers

Raj Tummala, Tomas Rouse, Anna Berglind et al. · Lupus Science & Medicine · 2018 · 33 citations · Full text